Submission of new drug information
First Coast accepts information regarding new drugs, new or revised indications, or marketing materials for forthcoming drugs or...
Transcatheter aortic valve replacement (TAVR)
Important information notifying users of the requirements for approval of transcatheter aortic valve replacement (TAVR) studies.
‘Reasonable and necessary’ guidelines
View these guidelines regarding what it means for a service to be "reasonable and necessary."
Retirement of LCDs and local coverage articles
View these reasons why First Coast may consider retiring LCDs and articles.
Pre-market approval (PMA), PMA post-approval studies, pre-market notification (PMN) 510(k), and 510(k) post-approval extension studies
Read about pre-market approval (PMA), PMA post-approval studies, pre-market notification (PMN) 510(k), and 510(k) post-approval...
Billing and coding of routine costs
View these billing and coding instructions of routine costs for qualifying clinical trials.
Contractor advisory committee (CAC) meeting minutes
View CAC meeting minutes from our meeting on February 19, 2026, on the use of urine-based biomarkers in patients with...
Proposed local coverage determination: Contractor advisory committee (CAC) meetings
Contractor advisory committee (CAC) meeting information and upcoming CAC meetings
Assist us in developing LCDs
Join First Coast's Contractor Advisory Committee (CAC) to provide your input during the development process of LCDs.